Catatonia according to ICD-11 criteria
Conditions
Interventions
Group 1: Longitudinal observational study of catatonia patients with different underlying diseases over a period of 12 months.
Patients with catatonia according to ICD-11, and Bush-Francis Catatonia
Sponsors
Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Würzburg
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Understanding of the study, ability and willingness to participate in the study - Ability to provide written informed consent as documented by signature ( Informed Consent Form) - Patients only: Catatonia diagnosis according to ICD-11 and presentation with a BFCRS of > 2. - Multiple study participation is possible for catatonia patients if patients present with a novel catatonia episode following remission of the previous one. - Clinical/patient controls only: matched underlying disorder, age, gender
Exclusion criteria
Exclusion criteria: None for general participation in the study, however, specific limitations apply for MRI and TMS: - Standard exclusion criteria for MRI scanning and TMS only: E.g. Medical or metal implants (retainer, pacemaker), claustrophobia, pregnancy, hearing problems/Tinnitus - Healthy controls only: own history of any severe mental disorder or first-degree relatives with Psychotic disorders (Bipolar, Schizophrenia). - Clinical/patient controls only: own history of catatonia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome measures are the catatonia rating scale scores that will be obtained from the clinical evaluation. Catatonia severity will be measured by the change of the BFCRS (motor rating scale specific for catatonia) from baseline to week 4 (or prior if BFCRS <2), week 25 and week 50. | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical outcomes include treatment response and course of general psychopathology. The response to treatment (reduction from baseline BFCRS) between groups/categories of associated psychiatric/medical condition at different time points will be assessed. Changes in general psychopathology using the positive and negative syndrome scale PANSS and the brief negative symptom scale BNSS (for psychosis) or MADRS ( for depression) or YMRS (for bipolar disorder) between baseline, week 4, week 25 and week 50. Change in self-reported physical activity and experienced negative symptoms using the International Physical Activity Questionnaire (IPAQ), the self-evaluation of negative symptoms (SNS), Northoff self-report (NSSC) and Sensorimotor and Activity Psychosis-Risk (SMAP-R) Scale from baseline, at week 4, week 25 and week 50. Behavioural outcomes: Change in objective gross motor activity as measured durch wrist actigraphy at baseline, week 4, week 25, and week 50. Change in fine motor function as measured with the coin rotation task and grip force measurement at base-line, week 4, week 25, and week 50. Neurophysiological outcomes: Changes in motor cortex excitability from baseline to week 4 and 25 will be assessed using a paired-pulse TMS paradigm. Neuroimaging outcomes: Differences in structural connectivity (using diffusion imaging) and fundamental measures of brain structure (eg. Grey matter density) at baseline assessment of structural MRI data. Changes in resting state perfusion within the motor network from baseline to week 4 and week 25 in patients treated for catatonia. Changes in motor network resting state connectivity from baseline to week 4 and week 25 in patients with catatonia. | — |
Countries
Germany
Contacts
Public ContactMira Semmelroch
Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Würzburg
Outcome results
None listed